ESG Report 2022

Drug innovation and medical accessibility continue developing and improving its medicines to meet the to receive widespread attention from the global needs of an ever-changing market. The Group is pharmaceutical and intellectual property fields, and also committed to promoting the development of are related to the development of public health and the industry and promoting pharmaceutical the balanced development of pharmaceutical academic knowledge and information through intellectual property rights. In order to enhance the academic promotion projects. The Group has Group’s innovation capacity and competitiveness formulated The United Laboratories Methods of on the market, The United Laboratories is Intellectual Property Management to protect its c omm i t t e d t o i n n o v a t i o n , r e s e a r c h a n d brands and pharmaceutical patents from any development, establishes multiple research and infringement. development platforms, and is constantly 4.1 Innovation and R&D The Group continues to strengthen its investment in medications, ophthalmic medications, veterinary R&D and innovation, build different pharmaceutical medicines, etc. The production process and R&D platforms, and strive to develop and improve production technology of drugs, environmental more high-quality and safe drugs to make greater protection transformation and intelligent contributions to human health. The direction of the transformation are also one of the directions of Group's research and development of drugs R&D and innovation. We are committed to using includes new drugs and high-value generic drugs. better technology to provide our customers with the Key research and development areas involve best quality pharmaceutical products. endocrine medications, autoimmune disease The Group has established the Biological, institutions with national drug clinical trial Medicinal Chemistry, Medicinal Innovation qualifications and authoritative treatment in related (Chemical Drugs) Research and Development fields. Under the guidance of well-known experts in Institute and the Clinical Medicine Research Centre the Country and abroad, we have organised and to cooperate in research and development. The completed more than 80 clinical trials of research institutes are equipped with research pharmaceuticals. At the same time, the Group also talents and advanced equipment. The Biological cooperates with universities, research institute, and Research and Development Platorm has nearly 420 laboratories in the Country and abroad to carry out research and technical personnel, and the research and development work. proportion of personnel with graduate or above academic qualification exceeds 30%. At the same time, it is equipped with more than 100 large-scale research and development equipment with leading technologies in the Country and abroad. The investment in assets exceeds RMB160 million. The Medicinal Chemistry Research and Development platform is responsible for the consistency evaluation for the quality and effectiveness of the Group's Medicinal Chemistry and generic drug, with nearly 150 research personnel and having a proportion of personnel with graduate or above academic qualification exceeds 63% in the Medicinal Innovation ( Drugs) Research and Development Platform. The Clinical Medicine Research Centre is responsible for the design, organisation, implementation, quality management and compliance and related work of all of the Group's clinical trial projects. It also closely cooperates with more than 100 domestic Chemical 4.1.1 R&D Platform Environmental, Social and Governance Report 2022 The United Laboratories International Holdings Limited 11